DOI:
10.1055/s-00043364
Pharmaceutical Fronts
LinksClose Window
References
Li JY, Perry SR, Muniz-Medina V. et al.
A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy.
Cancer Cell 2016;
29 (01) 117-129
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.